Epinephrine study
This article was originally published in The Tan Sheet
Executive Summary
"Nonprescription epinephrine CFC-MDI is more effective and safer than what many health care professionals believe," a study in the December Annals of Allergy, Asthma & Immunology concludes. Wyeth's Primatene Mist OTC metered-dose inhaler was "nearly" as effective as GlaxoSmithKline's prescription MDI Ventolin (albuterol) in "terminating an acute episode of airway obstruction but safer at higher doses," Leslie Hendeles, Health Science Center, University of Florida, et al., found. The randomized, cross-over study was conducted on two different nights at a clinical research center. The eight patients were administered albuterol upon waking from asthma symptoms on one night and epinephrine the next. "A study with a larger number of patients is required before epinephrine can be recommended as rescue therapy when prescription beta2-agonist MDI is not accessible," the authors state. The necessity of OTC chlorofluorocarbon-MDIs will be discussed at an advisory panel meeting Jan. 24 (1"The Tan Sheet" Dec. 5, 2005, p. 5)...
You may also be interested in...
CFC Use In OTC Epinephrine Inhalers Topic Of Upcoming NDAC Meeting
FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs advisory committees will discuss the availability of OTC epinephrine metered-dose inhalers (MDIs) and their environmental impact during a joint meeting scheduled for Jan. 24.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.